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Abstract. Especially in the area of genomics, global research institutions
constantly provide new insights. Yet today we lack insight on how the use of
research data in clinical practice is facilitated. Our study researches an
entrepreneurial venture as complementing actor in the international health
context who bridges data use from research to science. In this paper, we present
a three-step framework how the venture legitimizes data-driven services to
facilitate research data use in clinical practice. Our findings illustrate that the
venture managed to adjust to clinical needs by using three mechanisms: 1)
assessing and aggregating, 2) allowing for ambiguity and 3) assuring clinical
assistance. This study adds to the understanding of new ventures’ services
legitimation scaling across traditionally national healthcare with local systems.
Moreover, our framework is of interest to entrepreneurs and investors, who seek
entrepreneurial opportunities and information about ventures that have been able
to navigate this field.
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Introduction

Genome data and genetic medicine have promising global advancements such as
personalized medicine, new diagnostic methods and new disease treatment that are of
relevance to humankind [1–3]. Genetics is a field that benefits greatly from the
digitalization of research data. Borders between research and application are blurring
in genetics, because the ongoing research efforts have direct relevance in healthcare
practice [4]. It is thus becoming increasingly relevant to integrate highly international
and research-centered efforts into local (national) medical practice [5]. This is not an
easy task, as scientific research and healthcare institutions currently work separately
from each other, pursue different goals and use different information systems [6].
Information systems (IS) researchers have pointed out these challenge and the need to
include the field of genetics to advance IS research [7–9].
How to use the ubiquity of (research) data? That is a relevant question, it has only
played a minor role in health IS research which has often discussed national projects in
context of national healthcare. We follow an earlier research call to explore how
research flows into clinical applications [5] and show the novel possibilities that
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entrepreneurial ventures can take in healthcare [10], serving new and complex needs of
various stakeholder groups.
We are especially interested in new venture-provided services in biological,
specifically human genome data [11, 12]. Our study researches a data-intensive, young
firm (entrepreneurial venture) as a complementing actor in international health services
[9, 13]. Our research question is: How can a third-party venture legitimize new data
services to facilitate research data use in healthcare? In our empirical case study, we
explore a venture that supports sharing and generating insights between international
researchers and healthcare practitioners. We explain how the venture establishes new
services for a heterogeneous range of stakeholders.

2

Background

2.1

From Traditionally Local to International Context of Healthcare

In today’s IS health literature, the “durability and central role of existing practices,
conventions, tools and systems” [14] is often central to studying the challenges along
the lifecycle of building, adapting and evolving local health systems and information
infrastructure in national healthcare [15–18]. Healthcare research seldom refers to
international projects that establish or adapt healthcare related services with digital
technology. The focus on a siloed setup in local healthcare settings ties traditional
healthcare research to addressing challenges with a rather localized view [15, 19–21].
But comparably new and recent fields for medical treatment rely on cross-institutional
and cross-national collaboration and data exchange [22, 23].
Data-related problems impact healthcare sector globally: Western countries as well
as developing countries experience difficulties in ensuring that data are standardized
[24] are safely shared [21, 25], available [26] and lead to legitimate services [20, 27].
For analysis in clinical diagnosis, the representation of health-related problems in data
is paramount: In data-heavy fields like genomics, access to these data and the need for
sharing initiatives are the desired path to advance clinical practice [2, 4, 28, 29]. Little
standardization exists, and large datasets grow incessantly [30–32]. The shift of
attention from local healthcare concerns to global communities is appropriate as data
digitization is transforming healthcare [24, 33, 34] as it removes limitations of physical
access while also “dissolv[ing] product and industry boundaries” [35].
2.2

The Role of Data in Clinical and Research Context

Today, healthcare and research institutions are working with different stakeholder
groups. Healthcare institutions involve distinct stakeholders—patients, insurance
companies and medical practitioners—relying on the existing prevalent clinical
problems and proven diagnostic guidelines [15, 17, 18]. In contrast, research institutes
take up risks to find methods, diseases and cures that are unknown to date and explore
large sets of new data in collaborative and country-spanning programs [6, 36]. Indeed,
researchers have often distinguished between clinical institutions (healthcare, as in

hospital or care institutions) [14, 18, 19] and research institutions [37–39]. This
separation conveys the impression that they are not connected, yet as mentioned in the
previous chapter, data is the blood that runs both in the veins of research and healthcare
institutions [30, 40, 41]. Thus, we do not believe that the division of discovery and
application to different kinds of organizations is the best way to approach this issue
[21]. Surprisingly, data as a resource is only infrequently discussed in health IS
literature on research and clinical institutions. Scientific institutions could not directly
care for the data (re)use in healthcare [6], and while international patients exchange
forums (Patients Like Me) are rather common by now [42], we know little about the
involvement of clinicians and researchers in such areas. We think the assumptions
behind this rather limited view of health-related matters should be challenged [5]. Data
are the basis for both of these activities (research and clinical) and should be focused
on [29, 33, 37, 43].
2.3

The Role of Third Parties in Serving New Healthcare Needs

As digitization and data sharing across countries facilitate the collaboration of
multiple organizations, third parties can also take a role in previously less digitized
fields such as healthcare [11, 44, 45]. A third-party firm as incumbent might act as an
intermediary, as the involvement of third-party firms has several interesting benefits to
healthcare:
First, with digital services, the venture is likely to aim for growth of its user base
[46, 47] and establish a proposition to fit more than one organization. If successful, the
complexity of adapting to the broad range of healthcare stakeholders could be avoided,
and healthcare would be freed from the burden of deeply local IS transformation
projects [13, 17, 21]. Meanwhile, it could have a greater effect—that is, reach more
communities in healthcare overall. Second, ventures seek to establish new services and
innovative solutions [48] and might compensate for limitations that existing healthcare
institutions would have been hindered from overcoming once principles for their local
IS systems are defined [14]. Third, while digital technology ventures have an interest
in quickly appropriating value from their work and achieve growth [46, 49, 50], they
also seek legitimacy from existing structures [51, 52]: experimenting and probing with
the right standards of digitized data and technology in a strictly regulated field, can be
applied with existing procedures that are key to healthcare organizations, too [52–54].
Within the realms of entrepreneurial ventures in other sectors, we find different
strategies used to navigate in such new markets [54], but in healthcare, we know little
about how such industry-spanning ventures bring different requirements together.
2.4

The Context of Genomic Health

In healthcare, all diseases are somehow mirrored in genetic components, and
knowledge regarding genetic pathology is constantly growing [3]. Technological

progress has lowered the cost of genome sequencing over time, and an increasing
number of healthcare practitioners now use genetic data for diagnostics [44, 55].
Research institutions have access to large scalable infrastructure for use in basic
research because sharing, collaborative problem solving and open experimentation are
crucial for scientists when tackling complex questions [37]. The existing IS systems in
research are tuned toward processing large amounts of data to find new patterns. Data
governance and quality in the related science repositories are not necessarily suitable
for healthcare organizations [7]. Healthcare institutions need data from research to
verify their findings [56, 57]. They may risk ignoring new knowledge or over- or
underestimating the impact of their findings by finding other, similar cases [58, 59]. A
genetic diagnosis that has not been validated primarily affects patients who run the risk
of receiving an inaccurate diagnosis, living with uncured pain, or succumbing to death.
Reference systems could be provided eventually, but would be general in purpose;
establishing those will take years to come [23]. The activity of firms that prepare data
and offer their exclusive services for commercial fees [7, 29] is not beneficial for
countries that have little means to afford such access. However, the interest in
simultaneous research and diagnostic use has increase the interest in entrepreneurial
ventures in health [9, 13].

3

Case Description

Our case investigates an entrepreneurial venture in Switzerland that leverages openly
available scientific data to support the intersection of research and healthcare practice.
Established in 2013, the company provides services to over 200’000 users across the
globe, namely Asia, North and South America and Europe. The case company vision
is to create a genome data service for various interest groups with most essential
information on genetic variants and their documentation, annotation, connection and
classification. Users can access all services online via a web-based search application
that leverages data pre-processed primarily from research sources, including more than
50 internationally acknowledged data repositories. These include RefSeq, ClinVar
(National Center for Biological Information), gnomAD with more than 120 single
investigators and contributing projects, and numerous additional data sources. The
venture runs its service across 33 billion data points.

4

Methodology

Our goal is to provide explanations [60] that allow a better understanding of research
data use in healthcare, second, for the role of entrepreneurial ventures in gaining
legitimacy to establish the respective services to facilitate the data use. Thus, an indepth understanding of the phenomenon requires us to consider multiple sources and
means of data collection, as well as a long preparation phase in which we understand
the context of the science, healthcare and genome data infrastructure. We present an
unusual and revelatory case in health IS that is best understood using an embedded case
study [61]. The uniqueness of our case shows in distinctive attributes, compared to

other small ventures. First, there is the market success of this venture. It has enjoyed a
two-digit growth rate in the last five years and has reached by now over 200’000 users.
These users come from over 120 countries and underline that the venture’s services
address global needs. In this study, we expect to observe the factors that resulted in the
venture’s legitimacy, as the. We understand that the opposing needs and settings of
science’s and healthcare’s data use are complex to address. In contrast to other
entrepreneurial ventures that operate either for healthcare or science, our case company
refers to both worlds and bridges a gap that is hardly visible in previous papers. This
has been confirmed once we had talked to users, who refer to this venture’s services as
their main reference points. Finally, the venture has a pioneering status due to its
comprehensiveness for over 50 data sources from different data sources and ease of
use.
Having gathered extensive background knowledge from the industry, we observed
the firm as a first unit of analysis for 2 years and included the users as a second unit of
analysis. Hence, we exclude with relative certainty the possibility that “the issues that
motivate our study are (sometimes) stated as imaginary pseudo-problems” [62].
4.1

Data Collection

The interview data were collected during semi-structured interviews, which were
held in English. The questionnaire for the first round of interviews focused on the role
of the employees (all in the leadership team), their motivation, and the description of
the product and its function, users, as well as their relationship to research institutions
and clinical institutions. Review meetings were held to confirm that the information
collected was still valid as stated in the interviews and to ensure that users could be
contacted. From 100 requests to users, 5 users signaled their willingness to participate
in interview. These users were asked about their role, the module and actual use of the
product and what they had used as a solution before they found it. All audio interviews
were recorded and transcribed.

Table 1. Data Collection

Level

Date

Industry

02/2017
–
03/2020

Firm

Users

4.2

Durat.

Record

Seminars on human genome
diagnosis; shadowing
laboratory staff in Germany

50 d
(400
h)

Notes

09/2018
–
08/2020

Workshops, attending
product demos, roundtable
with IS researchers in health
in three countries

30 h

Rec.

10/2018
–
12/2019

Interview with CEO, 10/18

70 m.

Rec.

Interview with CTO, 02/19

30 m.

Rec.

Interview with PM, 02/19

45 m.

Rec.

Update with CEO, 04/19

30 m.

Notes

Update with Product
manager, 12/19

20 m.

Notes

Interviews with current users
(MDs, researchers) of the
firm’s services in Mexico,
France, Turkey, Spain and
Iran

5 x 30
m.

Rec.

0103/2020

Description

Data Analysis

The analysis of all material was performed with MaxQDA. Applying inductive
principles of Gioia [63], we created a rich set of codes, resulting in a pattern and a set
of 1st order themes close to the informants’ expressions. Though iterative literature and
data analysis, higher-level, 2nd order themes were created. Finally, aggregated
dimensions helped us explain how new services were created and legitimized by the
ventures. Findings were also discussed with two non-authoring researchers.

5

Findings

Figure 1. Findings of Venture’s Mechanisms

We present our findings referring to the 1 st order concepts and proceed with the
explanation of the aggregated dimensions in the next chapter.
5.1

Establishing Common Ground

The firm downloads the data from research repositories and processes all data in
their proprietary physical servers in Switzerland. This data dump is then transformed
to fit one database model with consolidated metadata (handled in what is like a mapping
of different databases). This requires disambiguation, transformation of formats and
cleansing of data. The firm stores the data and the associated meaning, including
comments and relationships, in separated structures for faster retrieval of the required
data in context of the command entered by users. Disease prediction mechanisms are
applied and re-calculated daily, based on the insights from single databases.
(a) One of the classic problems whenever you deal with sequences in biology each
database has its own identifier. So, the same gene can be known in at least 20 different
ways. (…) So, we will have tables that combine this information to allow me to go from
ensemble transcript identifier to a the equivalent refseq identifier. That is a data
process that we will set up. (…) That tells me where the gene is located, the start
position the end position the exomes et cetera were found. literally an own table in the

MySQL database. So, what we will add is the table that links the different identifiers
that helps us communicate between the different data sources and databases. (PM)
The service provides a threshold by which it shows disambiguated results for a
disease-causing meaning of the variant, in addition the variant meaning is classified
with an applied standard by American College of Medical Genetics (ACMG) for
healthcare. All services in their Product (Product A) access the two structures but
returns depending on the services. The CEO would not want to interfere with the
domain knowledge of genetics. Instead, they engage with stakeholders of the platforms
like ClinVar to ensure their offering is adjusted to a common understanding of the
“industry standard”. Based on the industry understanding and new tools being created,
the users (often medical doctors, but also researchers at the same time) would see the
firm provided updates in the service to do justice to new best practices in the
community. All available data and analysis tools in the web interface include
relationships to classification for healthcare, clinical meaning and various other
attributes. Once the results were returned, there appeared numerous options for a drill
down and exploration, which always returned the respective associated knowledge
from different sources. The new information first went to the interface for researchers
and free users: That interface was free to access, the firm uses it to test and validate
new functions, standards it had imported and data it loaded.
(b,c) It gives the – prediction average of 21 prediction tools. It makes an average.
And I already, I trust its rather than a mutation tester (…) because revel includes an
average prediction. So, I am very pleased to see Product A to include it in recent
months. (User from Turkey)
5.2

Encouraging Global Contributions from Researchers and Clinicians

When users access the services, they do not only see the result and a visualization of
the attached meaning (variant finding related information for example from a specific
ethnographic group, publication on the variant, suggestions for variant-associated
diseases, prediction tools for the variant effects…). The user would also be able to
common on the finding with own contributions. In fact, finding comments of other
medical professionals or researchers would be useful to verify the retrieved information
and also correct the data where meaning (classification = pp is pathogenic, disease
causing) could be put into context. That is important to know, because users would
come from various backgrounds and the meaning of a variant in, say, leukemia would
be different from a variant that is researched related to kidney cancer. Also, phenomena
that span the globe could be identified and shared, as a user (researcher and medical
doctor) from Mexico explained.
(e) I have seen that others, other people in other laboratories, many Asian, they
have seen some of our variants that we classified, I guess they are seeing them or they
are recommending them also because that is a linked with their patients and our
patients in this variants of uncertain significance. (User from Mexico)

This effect was carefully deployed by the venture due to its supporting effect for
both quality and legitimacy in the community. A researcher who found others’
comments (mostly also with a short note on the affiliation and background of the
individual) would allow them to see which legitimation it had in eyes of other
researchers of similar or other disciplines. Both firm and users explained us that the
free services are “tuned” towards a reinforcement of clinical use – to both encourage
contribution and to avoid too much free riding. Once the limitation of 100 free searches
is consumed, the firm requests users to contribute back to the community with a
classification of a variant. While the user is not forced to contribute, the firm leverages
the implication (speed decreases) to encourage the user to contribute.
(f) It actually helps a lot because all the feedback we get from the community helps
us make it better. Especially as I said when there is a lot of room for interpretation of
any data. We launched it here first. We get feedback from a thousand people let's say.
It's of course a variant quality and we have to use our judgement to see who is liked
and who is most likely to be more reputable. (CEO)
The set-up of the services considers possibilities of discovery, with is relevant where
new insights appear (so called “de novo” findings, with little experience and data to
refer to). The community was required to assess and contribute, either in the sources
that the firm pulls in, or in the actual service interface to converse about the clarification
and generation of new knowledge. For established findings on variants with associated
diseases, the services encouraged refinement and re-use of knowledge which exists in
various existing platforms through their commenting function and daily loads of new
information. A user from France who faced a very rare condition in a patient was able
to contact the respective user who had contributed to the classification of the candidate
gene, who then allowed him to achieve a confirmation of the phenotype and diagnosis.
(g) So today, we’ve been able to identify a new candidate gene, thanks to Product A,
another variant which was disturbing because, the phenotype was quite severe and did
not know if the variant was really pathogenic. And Product A was really useful to
connect to the patient with the same variant (User from France)
In addition, we found that the researcher and medical community included less
privileged participants. Being deprived of other possibilities, the user from Iran
regarded the possibility to collaborate via webservice as a unique opportunity to share
his knowledge and benefit from a wider range of contributors he would otherwise not
have access to.
(h) Users can see my classification and it’s easy for them to decide if a variant that
they identified is pathogenic or not. I always try to do this, because I think it’s helpful
for others. But we are underdeveloped country, it is very hard for us to manage or
design a system to help people. People in the country, but you as a developed country
it’s easy for you, you can collaborate all around the world. (User from Iran)

5.3

Accounting for Distinct Clinical Requirements

Another service that the firm offered was specifically built for clinical use in
diagnosis, it also had to be In Vitro Diagnostics (IVD) certified and was only available
for a fee. This service serves as an extension to diagnostic analysis for doctors who had
an entire patient sequence available. The firm checked for personal data attributes
(names, address, etc.) and would delete such attributes if contained. The genome then
could – only with one click- be annotated (show the different assessments and degrees
of pathogenic variants, the associations with diseases and reference data from various
sources). Then, the venture had ensured that the user would receive a snapshot which
annotations at the time of the upload and annotation. As the knowledge of the human
genome still progresses, the user needs a justification that he used the knowledge
available at the time.
(l) This is an advanced clinical platform. For example, it contains pictures such as
audit trails. In other words, it tracks your uses of the platform in case there's ever any
legal issue. (..) On Product A here, we keep updating the data. Here we keep updating
the data for new analysis of new patients. If you have analyzed a patient the data is
frozen exactly to the state of the day of the analysis, so that there's no issue afterwards.
The knowledge that was available on that day allowed us to produce this report. You
can also create a diagnostic report. (CEO)

6

Results and Discussion

Our study looks at a venture that uses more than 50 large genetic research sources to
facilitate its use in a medical context. We find that the third party uses three mechanisms
to legitimize their services [64]: 1) assessing and assigning weight, 2) allowing for
ambiguity and assertion, and 3) assuring clinical assistance. These mechanisms are
prerequisites that must be fulfilled for the venture to legitimize these data services. The
venture applies them sequentially (1, 2, 3) and independently in order to successfully
achieve legitimacy. We describe them in more detail.
6.1

Assessing and Assigning Weight

The venture represents itself as a partner to organizations to reduce uncertainty and
provide support in standard-setting. In lack of one standard, they consolidate standards
to apply with hand-selected, curated and processed data sources, which reduces also the
uncertainty for the venture: A combined reference may be a factor enhancing timeliness
and disambiguation as more contributions – also contradicting ones- are included [8,
65]. In overcoming the rigidity of a one-standard-system that would hold data in a local
healthcare infrastructure, the venture as arbitrator separates the data itself from the
context they are used in (literally saving them in different places) and shows data even
when there are contradicting insights that come from various groups (example: from a
rather breast-cancer-focused database from research, applying a data standard that
mostly clinicians use). Data silos are a problem which is well known in clinical context,

the low transparency of the related silos producing data [21, 66] is mitigated with this
third party involvement. Leveraging known standards in their innovation of IS [67, 68]
they can ensure a reference point of “known” trusted settings from clinical settings and
at the same time keep generativity of data high [24].
6.2

Allowing for Ambiguity and Assertion

The users of the venture’s services also work at the intersection of the institution
types (as researchers and laboratory workers for clinical labs, or as medical doctors who
pursue research interests, too). For the venture, research and practice are just as closely
intertwined as genetics [5, 69]: This ambiguity of roles is acknowledged as the data can
be enriched with new interpretations. In a dynamic field as genetics where new data
and classification are added [70] the venture can only prove its legitimation of the
service when it allows references to be established by its users who are discovering and
using the data themselves in various settings [45, 52]. The online exchange on the
venture’s webservice are openly and globally accessible and allow of diverging
opinions, uncertainties and connections like a non-medical or non-professional online
forum [15, 33, 71]. That also provides a non-threatening context to clinicians and
researchers, where they are not judged.
6.3

Assuring Clinical Assistance

Finally, the clinical service of the venture seeks to transfer physical medical
standards to digital processes. The In Vitro Diagnostics (IVD) certified procedure, for
which also humans have the responsibility in the end. Attaching evidence of the
references used (data sources, annotated reports and justification documents for data
used) it is closest to the procedure clinicians know [52]. Task-related procedures instead
of fully integrated systems could support also from external providers. Activities of
such complexity, split into modules as the venture does, then, would only lead to small
transformations that do not affect existing healthcare information systems [14].
In sum, that brings a totally new perspective to healthcare research, moving away
from additions to the local healthcare practice to cross-border service that can fit into
any healthcare system. Thus, the legitimation of new services can scale across sectors
and countries. Instead of holding one person right away accountable for a comment, the
venture promotes easy access for exchange [72]. The peer validation and feedback
mechanisms remind us of the open source movement. The meaning of different findings
is discussed and validated in the context of each user. That context can be very different
and diverse, but with global contributions, weighs more [73]. Local healthcare
information systems are much less flexible [8, 14]. There, a change project for installed
base systems is likely to span years and would be unlikely to generate such scale as
they work local, are locally regulated and have a limited set of data, too [14, 21].

7

Conclusion

Within a dynamic and data-rich environment, where research and clinical borders
blur, third parties can add to the healthcare landscape by offering new services. In our
study, we observed a venture that addresses both research and healthcare stakeholders,
who usually find themselves working in segregated systems without touchpoints. We
find that the venture brings stakeholders from both sides together via their new services.
The case shows that different mechanisms of legitimation are enabled through digital
technology through mirroring what has been considered a relevant reference (e.g.
framework, certification) in clinical practice. Moreover, as the three mechanisms work
independently from established national healthcare systems but greatly enhance the
work of clinicians, we see these as modular elements that can scale legitimation of new
services. With these contributions, we call for more research on the role of ventures as
intermediaries within healthcare in a dynamic and complex field such as genetics.
Our findings have clear limitations. In our single case study, we reveal first
mechanisms that help us understand how a venture uses technology, both scientific and
healthcare communities and established certifications to legitimate its services. More
research on other organizations increases the external credibility of our findings;
focusing on a single case by necessity leads into questions about transferability of
findings to other cases. As our findings may not apply to all ventures, we add three
boundary conditions that describe how to identify “similar” cases. We hope they help
guide other researchers on how to determine the applicability of our findings [74]:
(1) Use of technology is appropriate and configured by one or more
stakeholders (decide how it should be done)
(2) Involvement of communities is feasible and allowed (to delegate the
legitimation mechanisms in part to others)
(3) The necessity of validation and achieve legitimacy is open to a range of
legitimacy values (in our study: either clinical, scientific exploration etc.)
If one of these prerequisites is not met, the degree of legitimation we have shown in
our study needs to be re-assessed. However, we see no reason to not to believe that the
mechanisms identified in this single case study would be dramatically different in other
potential organizations. Thus, we hope to deliver a basis for future work on data
ventures.
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